No Data
No Data
No Data
No Data
No Data
Benign Growth For Amicus Therapeutics, Inc. (NASDAQ:FOLD) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 7.6x Amicus Therapeutics, Inc. (NASDAQ:FOLD) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the United
Simply Wall StApr 28 20:54
As More Rare Disease Therapies Launch, Their Prices Are Rising
Seeking AlphaApr 17 00:22
Form 144 | Amicus Therapeutics(FOLD.US) Director Proposes to Sell 311.67K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Amicus Therapeutics(FOLD.US)$ Director JOHN F CROWLEY intends to sell 29,183 shares of its common stock on Apr 15, with a total market value of approximately $311.67K.
Futu NewsApr 16 04:31
Amicus Therapeutics(FOLD.US) Officer Sells US$87,495.75 in Common Stock
$Amicus Therapeutics(FOLD.US)$ Officer Campbell Bradley L sold 7,500 shares of Common Stock on Apr 1, 2024 at an average price of $11.6661 for a total value of $87,495.75.Source: Announcement What is
Futu NewsApr 4 06:57
Form 144 | Amicus Therapeutics(FOLD.US) Director Proposes to Sell 343.75K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Amicus Therapeutics(FOLD.US)$ Director JOHN F CROWLEY intends to sell 29,181 shares of its common stock on Apr 1, with a total market value of approximately $343.75K.
Futu NewsApr 2 04:29
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Simply Wall StApr 1 19:39
No Data
No Data